Evaluate Retention Rate of Topiramate, Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment

Seoul National University

Status: Unknown

Conditions: Epilepsy

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02098941

0620133760

Details and patient eligibility

About

The Objective of this study is to compare 2-year retention rate of topiramate, levetiracetam and oxcarbazepine in a long term epilepsy treatment.

Full description

Primary objective The Objective of this study is to compare 2-year retention rate of topiramate, levetiracetam and oxcarbazepine in a long term epilepsy treatment.

Secondary objective The main secondary objective of this study is to evaluate confounding factors associated with retention rate of topiramate compared with other anticonvulsants.

1. Baseline characteristics

   • Seizure Type
   • Gender
   • Age of onset

2. Treatment regimen

   • Number of concomitant medication
   • Type of drug combination
   • Final target dose
   • Titration speed

Other secondary objectives

The other secondary objectives of this study are to compare followings by each medication:

• Rate of seizure reduction (≥75%, ≥50%)
• Rate of seizure freedom

Enrollment: 2,500 estimated patients

Sex: All

Ages: 15 to 95 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects who began their treatment with topiramate, levetiracetam or oxcarbazepine as mono or add-on therapy with conventional drugs.
• Subjects who are with partial or generalized epilepsy

Exclusion criteria

• Subjects who administered combination therapy in topiramate, levetiracetam or oxcarbazepine
• Subjects who have past experience of surgery for epilepsy treatment
• Subjects who were not followed up for at least 1 year

Trial design

2,500 participants in 3 patient groups

Topiramate

Description:

Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with topiramate as mono or add-on therapy with conventional drugs.

Levetiracetam

Description:

Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with levetiracetam as mono or add-on therapy with conventional drugs.

Oxcarbazepine

Description:

Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with oxcarbazepine as mono or add-on therapy with conventional drugs.